GSK said it plans to start five Phase 3 studies for a gynecological cancer antibody-drug conjugate licensed from Hansoh Pharma after early promising data. The company’s decision expands the trial footprint for the asset into a broader late-stage program, reflecting how ADC developers are moving quickly from early efficacy into registrational strategies across multiple tumor settings. The update also underscores the competitive intensity in women’s cancers, where ADC platforms are being tested not only for efficacy but for how consistent they perform across histologies and lines of therapy.